Compare Archer-Daniels-Midland Co (ADM) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Amphastar Pharmaceuticals Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.99 (market cap $38.79B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Archer-Daniels-Midland Co is far larger — about 44.9× Amphastar Pharmaceuticals Inc's market cap, and Archer-Daniels-Midland Co pays a 2.58% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ADM | AMPH | |
|---|---|---|
Market Cap | $38.79B | $863.95M |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $30.81 |
52-Week Low | $56.00 | $16.87 |
Enterprise Value | $47.04B | $1.26B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $76.59, down 1.19% with a bearish technical signal despite recent earnings beats. The company raised its 2026 outlook after strong Q2 results driven by biofuels and crushing margins. Valuation appears reasonable with P/E of 20.93 and P/S of 0.45, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting 15% upside.
The stock offers value with solid dividends and improved cash flow, but faces execution risks and revenue pressure. Near-term catalysts include Q3 earnings and continued biofuels strength, while competitive pressures and margin compression remain concerns. The current price near support at $76 provides a potential entry point for long-term investors.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
